ArticleBioinformatics (Oxford, England)2026
GeoGAD: geometry-aware antibody design framework for complementarity-determining region precision engineering.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationAntibodies, as pivotal effector molecules of the immune system, neutralize pathogens through specific binding to antigens mediated by complementarity-determining regions (CDRs), highlighting the critical importance of precise antibody design in diagnostics and therapeutics. Despite significant advances in CDR design, current methods remain limited by inadequate modeling of geometric constraints, omission of multi-scale spatial relationships, and insufficient conformational representation capacity-factors that collectively degrade prediction accuracy.
resultsTo overcome these limitations, we present GeoGAD, a geometry-aware antibody design framework with Gaussian attention mechanisms. Key innovations include: (1) the introduction of rotational positional encoding to enhance geometric sensitivity; (2) a geometry-aware module that integrates multi-scale spatial features through dynamic message passing, adaptive edge refinement, and multi-edge-type coordinate optimization; and (3) a Gaussian attention mechanism that employs an edge-type-sensitive spatial Gaussian kernel to model long-range sequence dependencies, enabling focused attention on local critical residues while preserving global contextual modeling. Experimental evaluations demonstrate that GeoGAD achieves superior or comparable performance to state-of-the-art models across antibody sequence-structure co-modeling, CDR design, and affinity optimization benchmarks, particularly excelling in amino acid recovery rates (AAR) and structural accuracy metrics (RMSD, TM-score). By enhancing the design precision of antibody CDR regions, GeoGAD offers a geometrically consistent framework for the computational design of therapeutic antibodies. AVAILABILITY AND IMPLEMENTATION: The source code and implementation are available at https://github.com/WeiSongJian/GeoGAD, and the archival version for this manuscript is deposited at https://doi.org/10.5281/zenodo.18073443.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.